Non Neutralizing Antibodies to Tissue Type Plasminogen Activator in the Serum of Acute Myocardial Infarction Patients Treated with the Recombinant Protein

Summary

Recombinant tissue-type plasminogen activator (rt-PA) is currently used as a thrombolytic agent in the management of acute myocardial infarction (AMI). Since it is known that other recombinant proteins induce antibody formation when administered to humans, we determined the presence of anti-rt-PA antibodies in serial blood samples from 60 AMI patients (43 treated with and 17 without rt-PA). Blood samples were taken upon hospital admission, 15 days and 1, 3,6 months thereafter. A blood sample was also collected from 200 healthy subjects. Using an ELISA, anti-rt-PA antibodies were detected as serum immunoglobulins specifically binding immobilized rt-PA. AMI patients before treatment and normal subjects exhibited negligible levels of anti-rt-PA antibodies; both groups had only one outlier value. Fifteen days after rt-PA treatment, 2 AMI patients showed an increase in antibody titer beyond the highest normal value. This titer progressively decreased during the following 6 months. The antibodies from these two patients bound rt-PA both in a solid and fluid phase. They bound melanoma t-PA to a lower degree and did not bind urokinase type plasminogen activator at all, indicating specificity for t-PA. The marked temporal relationship between rt-PA infusion and antibody appearance indicated that antibody formation had been elicited by the infusion of rt-PA. Nevertheless, the lack of anti-rt-PA antibody interference with rt-PA function in vitro, along with the favourable clinical outcome of those patients having such antibodies would indicate that the appearance of anti-rt-PA antibodies does not interfere with the physiological fibrinolytic activity.

• References

• 1 Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991; 78: 3114-3124
• 2 Lijnen HR, Collen D. Congenital and acquired deficiencies of components of the fibrinolytic system and their relation to bleeding or thrombosis. Fibrinolysis 1989; 3: 67-77
• 3 The GUSTO Angiographic Investigators. The effects of tissue plasminogen activators, streptokinase or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615-1622
• 4 ISIS-3 Third International Study of Infarct Survival Collaborative Group. ISIS-3: a randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone amon 41, 299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753-770
• 5 Anderson HV, Willerson JT. Thrombolysis in acute myocardial infarction. N Engl J Med 1993; 329: 703-708
• 6 Reed BR, Chen AB, Tanswell P, Prince WS, Wert Junior RM, Glaesle-Schwarz L, Grosbard EB. Low incidence of antibodies to recombinant human tissue type plasminogen activator in treated patients. Thromb Haemost 1990; 64: 276-280
• 7 Fineberg SL, Galloway JA, Fineberg NS, Rathbun MJ, Huffed S. Immu-nogenicity of recombinant DNA human insulin. Diabetologia 1983; 25: 465-469
• 8 Gribben JG, Devereux S, Thomas MSB, Keim M, Jones HM, Goldstone AH, Linch DC. Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet 1990; 335: 434-437
• 9 Spiegel RJ, Spicehandler JR, Jacobs SL, Oden EM. Low incidence of serum neutralizing factors in patients receiving recombinant-alfa-2b interferon (Intron A). Am J Med 1986; 80: 223-228
• 10 Berzofsky JA, Bercower IJ, Epstein SL. Antigen-antibody interaction and monoclonal antibodies. In: Fundamental Immunology Paul WE. ed. New York: Raven Press; 1975: 151-159
• 11 Colucci M, Cavallo LG, Agnelli G, Mele A, Burgi R, Heim J, Semeraro N. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site. Thromb Haemost 1993; 69: 466-472
• 12 Haverkate F, Brakman P. Fibrin plate assay. In: Progress in Chemical Fibrinolysis and Thrombolysis Davidson JF, Samama MM, Desnoyers PC. eds. New York: Raven Press; 1975: 151-159
• 13 Lawson JH, Pennel BJ, Olson JD, Mann KJ. Isolation and characterization of an acquired anti-thrombin antibody. Blood 1990; 76: 2249-2257
• 14 Gibson J, Nelson M, Brown R, Salem H, Kronenberg H. Autoantibodies to thrombomodulin: development of an enzyme immunoassay and a survey of their frequency in patients with lupus anticoagulant. Thromb Haemost 1992; 67: 507-509
• 15 D’Angelo A, Della Valle P, Crippa L, Pattarini E, Grimaldi LME, Viganò D’Angelo S. Brief report: autoimmune protein S deficiency in a boy with severe thromboembolic disease. N Engl J Med 1993; 328: 1753-1757
• 16 Cicardi M, Bisiani G, Cugno M, Spaäth P, Agostoni A. Autoimmune Cl-inhibitor deficiency: report of eight patients. Am J Med 1993; 95: 169-17
• 17 Varela F, Andersson Å, Dietrich G, Sundblad A, Olmberg D, Kazatchkine M, Coutinho A. Population dynamics of natural antibodies in normal and autoimmune individuals. Proc Natl Acad Sci USA 1991; 88: 5917-5921
• 18 Pennica D, Holmes WE, Kohr WJ, Harkins RN, Veham GA, Ward CA, Bennet WF, Yelverton E, Seeburg PA, Heyneker HL, Goeddel DV, Collen D. Cloning and expression of human tissue-type plasminogen activator cDNA in E. Coli. Nature 1983; 301: 214-221
• 19 Rijken DC, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 1981; 256: 7035-7041
• 20 Ruiz-Arguelles A, Angles-Cano E, Perez-Romano B, Ruiz-Arguelles G, Deleze M, Alarcon-Segovia D, Gaussem P. Serum antibodies to distinct epitopes of the tissue-type plasminogen activator (t-PA) in patients with systemic lupus erythematosus. Am J Hematol 1995; 49: 109-114